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Effect of parathyroid hormone on elastase release from human poly-
morphonuclear leucocytes. Acute and chronic renal failure are clinical
states associated with secondary hyperparathyroidism and increased
catabolism. It has been suggested that elevated proteolytic activity is
present in the blood in these clinical states. It is, theoretically, possible
that the excess blood levels of parathyroid hormone (PTH) in patients
with these disorders stimulate release of proteases, since this latter
process is calcium dependent and PTH enhances entry of calcium into
cells. The present study examined the effect of PTH and its amino- and
carboxyterminal fragments on elastase release from polymorphonuclear
leucocytes (PMNL), and evaluated the mechanisms underlying such an
action. 1-84 PTH stimulated elastase release from PMNL in a dose-
dependent and time-dependent manner. This effect of the hormone was
abolished by its inactivation as well as by the presence of EDTA.
Verapamil, trifluoperazine and W-7 reduced but did not abolish the 1-84
PTH-induced stimulation of elastase release from PMNL. Phorbol ester
(PMA) also stimulated elastase release but both PTH or PMA-induced
elastase release was blunted by staurosporin, an inhibitor of protein
kinase C. The 19-84 carboxyterminal P1'H also produced significant
stimulation of elastase release from PMNL but the amino-terminal 1-34
PTH or other peptide hormones (insulin, calcitonin, and ACTH) had no
stimulatory effect on elastase release. The results indicate that: 1)
PMNL are target cells for 1-84 and 19-84 PTH; 2) these hormone
moieties stimulate elastase release from PMNL; 3) the action is specific
to the PTH and is related to its biological activity; 4) the biological
activity of PTH that induces elastase release most likely resides in its
carboxyterminal fragment; and 5) this effect of PTH is mediated by its
ability to enchance entry of calcium into cells, causing alterations in
cytosolic calcium which would trigger cellular events leading to PMNL
degranulation and consequently elastase release.
Polymorphonuclear leucocytes (PMNL) contain a variety of
proteolytic enzymes that are released into the circulation during
degranulation of PMNL [1—31. The proteolytic activity of these
enzymes are neutralized in the circulation by inhibitors such a
1 proteinase inhibitor and /32 macroglobulin [41. However,
augmented and unrestricted release of proteases from PMNL
may cause injury to various tissues [1, 5—8]. For example,
PMNL elastase has been incriminated in degradation of glomer-
ular basement membrane in glomerulonephritis, in the destruc-
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tion of cartilage in patients with rheumatoid arthritis, and in the
digestion of lung basement membrane in patients with 1-
proteinase inhibitor deficiency.
Certain data suggest that elastase release may be enhanced in
patients with acute renal failure and to a lesser degree in those
with chronic renal failure [6, 9, 101. This phenomenon has been
implicated in the genesis of the catabolism in these patients.
However, the mechanisms underlying such augmented release
of elastase in these patients are not known and this phenome-
non has been attributed to uremic toxins.
It has been suggested that cytosolic free calcium is an
important regulator of PMNL activation [11—131 and factors
that may alter cytosolic calcium in the PMNL may affect their
elastase release. Indeed, Kokot et al [14] demonstrated that
elastase release from PMNL depends on the calcium messenger
system.
It is well known that both acute [15] and chronic renal failure
[16, 171 are states of secondary hyperparathyroidism, and
patients with these disorders have elevated blood levels of
parathyroid hormone, (PTH) [15—17]. This hormone augments
calcium entry into many cells [18—23]. It is, therefore, theoret-
ically possible that PTH may affect elastase release from
PMNL, and such an action may provide an explanation for the
increased elastase release in patients with acute and chronic
renal failure. Such a postulate finds support in previous obser-
vations demonstrating that the PMNL is a target cell for PTH in
that the hormone affects its random migration [241.
The present study was undertaken to examine the effects of
intact PTH and both its amino- and carboxyterminal fragments
on elastase release from human PMNL and to investigate the
mechanisms of such an action.
Methods
Elastase release from human PMNL was examined in whole
blood obtained from normal subjects. A total of 41 normal
subjects were studied; there were 19 females and 22 males and
their age ranged between 18 to 41(25.2 0.68) years. They all
had normal serum concentrations of creatinine (0.92 0.04
mg/dl), calcium (9.7 0.15 mgldl), and phosphorus (3.5 0.33
mg/dl).
Blood samples were withdrawn from the anticubital vein into
syringes containing 5 U of heparin for each ml of blood
884 Massry et a!: PTH and elastase release from leucocytes
(Thrombophob, Nordmark Co., Uetersen, FRG). One milliliter
of blood was centrifuged immediately for the measurement of
the basal levels of elastase in plasma. The remainder of the
blood was used for the determination of various biochemical
parameters and the study of the effect of various agents on
elastase release from PMNL. Since incubation of whole blood
is associated with spontaneous release of elastase from PMNL
and since this spontaneous release varied from subject to
subject and in the same subject from day to day, the effect of
any agent on elastase release was always compared with the
spontaneous release of elastase from PMNL of the same subject
in a simultaneous study of whole blood to which only the
vehicle was added. The vehicle was normal saline except when
otherwise indicated.
Several preparations of PTH were used. These included
purified 1-84 PTH, and synthetic 1-34 PTH (Sigma Chemical
Co., St. Louis, Missouri, USA), inactivated 1-84 PTH, pure
1-84 PTH and 19-84 carboxylterminal PTH. The latter two
moieties of the hormone were prepared in the laboratory of Dr.
James E. Zull, Cleveland, Ohio. The pure hormone was pre-
pared from defatted parathyroid glands which were obtained
from Sigma, and the hormone extracted and purified according
to methods described previously [25, 26]. The final purification
step was reversed phase HPLC which removes oxidized hor-
mone forms from the preparation. All HPLC separations
were done using a Waters system and reversed phase C- 18
u/Bondapak columns (7.8 x 300 mm). The solvent systems
employed were water/acetonitrile/trifluoroacetic acid mixtures.
The 19-84 PTH was prepared by cyanogen bromide cleavage of
1-84 PTH [26]. Both the pure PTH and 19-84 P1'H were assayed
for their activity in the renal membrane adenylcyclase bioassay
system by methods described earlier [271. The native hormone
was active while no activity could be detected for the 19-84
PTH fragment in this system. Inactivation of 1-84 PTH was
carried out as follows: 10 to 15 g of PTH was dissolved in 60
j.tl of 0.15 N acetic acid, and to this solution 40 d of 30% vol/vol
H202 were added. The solution was incubated at 37°C for 45
minutes, and the reaction was terminated by freezing and
lyophilizing.
We first carried out preliminary studies to examine the effects
of purified bovine 1-84 PTH. These studies showed that this
PTH preparation stimulates elastase release from human
PMNL. Studies were then conducted to evaluate both the
amount of 1-84 PTH and the time of incubtion required to
produce the optimum effect. Thus, both a dose-response curve
and a time-relationship curve were obtained. These studies
showed that 4 pg 1-84 PTH/ml and 120 minutes of incubation
produced the optimum results. Therefore, this dose of PTH and
this time of incubation were employed in further studies.
The following studies evaluating elastase release form PMNL
were carried out:
1. Dose response relationship between 1-84 PTH or 1-34 PTH
and elastase release.
2. Effect of 4 g of inactivated 1-84 PTH.
3. Effect of 4 .tg of pure 1-84 PTH and of 19-84 PTH.
4. Effect of 2, 5 and 10 U/ml of other peptide hormones
including insulin (H-Insulin Hoechst, Hoechst AG, Frank-
furt AM, FRG), calcitonin (Karil, Sandoz AG. Nurenburg,
FRG) and ACTH (synacthen, CIBA-GIEGY GmbH, Wehr,
FRG).
5. Effects of 2, 3 and 4 mrvt of EDTA (Sigma Chemical Co.).
6. Effects of l0—, 0.5 x i0 and 104M of verapamil (Sigma
Chemical Co.).
7. Effects of 0.05 x 106M and 0.25 x 106M of 4 /3-phorbal 12
/3-myristate 13 a-acetate (PMA).
8. Effect of iO, 0.5 x l0, 108M and 109M of Stauro-
sporin, an inhibitor of protein kinase C activity.
9. Effects of 105M trifluoperizine and of 25 M W-7, a highly
specific inhibitor of calmodulin.
In all studies equal volumes (50 l) of either the agent in
vehicle or the vehicle alone were added to 1 ml of whole blood
and then incubated at 37°C for 120 minutes except for the
studies of the time relationship. In these latter studies, the
incubation times were 30, 60, 120, and 180 minutes.
The blood samples were then centrifuged at 1500 g for 10
minutes. Elastase levels in the plasma were then measured as
elastase alpha 1-proteinase inhibitor complex (E a 1-PI) using a
highly sensitive enzyme-linked immunoassay (E. Merck, Sarm-
stadt, FRG) according to the method of Neumann et al [28].
Briefly, plasma samples were incubated with solid phase-fixed
antibodies against elastase. The fixed E a 1-PI complexes were
washed three times and then allowed to react with alkaline
phosphatase-labelled antibodies against E a 1-PI. The activity
of alkaline phosphatase is then determined colormetrically at
405 nm (Eppendorf PCP 6121, Eppendorf Co., Hamburg, FRG)
after the addition of 4-nitrophenylphosphate. The results are
expressed as ng/106 PMNL.
The concentrations of creatinine, phosphate, and total cal-
cium in plasma were determined by Technicon autoanalyzer
(Technicon Co, Tarrytown, New York, USA) and that of
ionized calcium by an AVL electrolyte analyzer 980 (AVL
GmbH, Bad Homburg, FRG). Stastistical analysis of the data
was done using paired t-test.
Results
The intact purified 1-84 PTH molecules (Sigma) produced
significant stimulation of elastase release from PMNL in a
dose-dependent manner with the maximum effect obtained by 4
g/ml (Fig. 1). At this dose the E a 1-PI was 122 18.7 ng/106
PMNL as compared to 89.4 12.2 ng/l06 PMNL with the
vehicle only, P < 0,01. This represented a 37 5.6% increase
in the concentration of plasma elastase. In contrast, 1-34 PTH,
in a dose ranging from 1 to 20 p.g/ml, had no effect on elastase
release (Fig. 1). The stimulation of elastase release by 1-84 PTH
increased with time of incubation and began to plateau after 120
minutes (Fig. 1). Inactivation of 1-84 abolished its effect on
elastase release from PMNL; in these studies the values of
E1-PI were 92.9 16.3 ng/106 PMNL with vehicle only, 138.2
24.7 ng/l06 PMNL (P < 0.01) with 1-84 PTH and 101.2
19.0 ng/106 PMNL with inactivated 1-84 PTH. This latter
value was not different from that observed with vehicle only
and significantly (P < 0.02) lower than that with active 1-84
PTH. It should be mentioned that in a small portion of the
studies with 1-84 PTH there was no stimulation of elastase
release from PMNL; in 14 of a total of 105 studies conducted
(13%), 1-84 PTH failed to exert its stimulatory effect.
Time, minutes PTH dose, pg/mi
Fig. 1. A: The effects of4 pg/ml of 1-84 PTH on the plasma levels of the elastase after incubation of3O, 60, 120, and 180 minutes (S). The plasma
levels of elastase observed after incubation with vehicle only for the same periods of time are shown (0). Eachdata point represents the mean value
obtained from 10 subjects and the brackets denotes I s, *p < 0.02 vs. time 0. B: Dose-response curves between the amount of 1-84 PTH (•) and
of 1-34 PTH (0) and the plasma levels of elastase after 120 minutes of incubation of whole blood with the hormone. The values of 0 PTH are those
obtained after 120 minutes of incubation of whole blood with vehicle only. Each data point represents the mean value obtained from 10 subjects
and bracket denotes I s. **indicates P < 0.05 and *indicates P < 0.01 vs. 0 PTH.
Table 1. Effects of insulin, calcitonin and ACTH on elastase release
from PMNL (N = 6)
0] _
Fig. 2. The effect of pure 1-84 PTH (0) and of the carboxyterminal
fragment 19-84 PTH () on the plasma levels of elastase after 120
minutes of incubation of whole blood with the hormone. Data from
simultaneous studies carried out with vehicle () and with 4 pg/mI (•)
1-84 PTH are also shown. Each column represents the mean of studies
from 6 subjects and the bracket denotes I SE. The values for 1-84 PTH,
19-84 PTH and pure 1-84 PTH are significantly different from those with
vehicle (P < 0.02).
Insulin
studies
Calcitonin
studies
ACTH
studies
Vehicle 64.0 10.0 99.6 19.9 118.4 24.6
PTH 4 pg/mI 85.7 9.2k' 129.1 24.3k' 159.8 32.3k'
Other peptides
2 U/mI 55.3 6.9 102.4 19.6
5 lJ/ml 51.5 50b 98.7 19.5
10 U/mI 38.0 40b 101.7 17.7
116.3 24.6
123.4 27.6
119.8 24.9
The values of plasma levels of E al-PI are the mean I SE and
expressed as ng/106 PMNL.
a p < 0.01 versus vehicleh P < 0.05 to 0.01 versus vehicle
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0.01) increase in plasma elastase levels after 120 minutes of
incubation. The plasma levels of E a 1-Pt were 86.7 20.5
ng/106 PMNL with vehicle only and 122.1 20.5 ng/106 PMNL
with pure 1-84 PTH and these levels were not statistically
different from those observed with a simultaneous study con-
ducted with Sigma 1-84 PTH (126.2 30.3 ng/106 PMNL).
Similarly, 19-84 PTH stimulated elastase release from PMNL
leucocytes; the plasma of E a 1-Pt levels after incubation with
19-84 PTH (78.6 15.2 ng/106 PMNL) were significantly (P <
0.02) higher than those observed with vehicle only (61.9 11.8
ng/106 PMNL) and were not statistically different from those
noted in simultaneously conducted study with Sigma 1-84 PTH
(84.3 18.6 ng/106 PMNL).
The effects of 2, 5 and 10 U/ml of insulin, calcitonin, and
ACTH on elastase release from PMNL are given in Table I.
None of these peptide hormones stimulated elastase release and
the plasma levels after incubation with calcitonin or ACTH
were not different from those observed with vehicle only and
were significantly lower than those observed with 1-84 PTH.
The effects of 4 pg/mI of pure 1-84 PTH or its carboxytermi-
nal fragment (19-84 PTH) on elastase release from PMNL are
shown in Figure 2. Pure 1-84 PTH produced a significant (P <
E 
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120 minutes of incubation of whole blood (vehicle: 105 10.7
vs. DMSO 86 9.6 ng/106 PMNL). PMA (0.05 X 106M)
produced a 60% increase (P < 0.01) in plasma levels of E a 1-PI
(169 5.1 ngIlO6 PMNL) as compared to the levels with vehicle
only (105 10.7 ngIlO6 PMNL). The simultaneous addition of
PMA and 1-84 PTH elevated the plasma levels of elastase to
values (218 15.9 ng/l06 PMNL) significantly (P < 0.05) higher
than those produced by PMA alone (169 5.1 ngIlO6 PMNL) or
1-84 alone (186 8.6 ng/106 PMNL), Figure 5. Higher concen-
tration of PMA (0.25 x 106M) produced an 80% increase (P <
0.01) in plasma levels of E a 1-PI (vehicle: 222.6 34.6 vs.
PMA: 400.0 84.8 ng/106 PMNL). This rise is significantly
higher than that observed with the lower concentration of PMA.
Staurosporin in a concentration of 0.5 x iO and 107M but not
of 108 and io— produced significant reduction in the PMA
induced elastase release of PMNL (Table 2). EDTA again
abolished both the spontaneous (vehicle) and PMA induced
elastase release. Staurosporin (107M) also significantly (P <
0.01) blunted PTH-induced elastase release (Table 3).
Trifluoperazine did not have an effect on the spontaneous
release of elastase from PMNL leucocytes (vehicle: 105 10.7
vs. trifluoperazine: 106 18.4 ng/106 PMNL) but significantly
blunted the stimulatory effect of 1-84 PTH on elastase release
(1-84 PTH: 186 8.5 vs. trifluoperazine and 1-84 PTH: 143
10.1 ng/106 PMNL, P < 0.02), Figure 6. The compound W-7,
which is a highly specific inhibitor of calmodulin, significantly
(P < 0.01) inhibited PTH-induced elastase release (Table 3).
Fig. 3. The effects of4 miv EDTA on the spontaneous (vehicle) and the
1-84 PTH-induced release of elastase from PMNL. Each column
represents the mean value observed in 6 subjects and the bracket
represents 1 SE. Symbols are: () basal; (El) vehicle; () 1-84 PTH
4g/ml; (•) EDTA 4 ms; (D) EDTA 4 msi + 1-84 PTH 4 gIml.
Insulin at a concentration of 5 or 10 U/mI produced modest but
significant inhibition of elastase release from PMNL.
The effects of EDTA on spontaneous (vehicle only) and 1-84
PTH-induced release of elastase are depicted in Figure 3. The
addition of EDTA to the blood had completely chelated the
calcium and the levels of ionized calcium were undetectable.
EDTA abolished both the spontaneous and 1-84 PTH-induced
release of elastase from PMNL leucocytes. The plasma levels
of elastase after 120 minutes of incubation with vehicle or with
4 g/m1 of 1-84 PTH in EDTA treated blood were not different
from basal levels of elastase. Similar effects were observed with
2 or 3 mt,i EDTA; in these studies the levels of E a 1-PI were
258 63 ng/106 PMNL with 1-84 PTFI and 52 5.2 and 45 6.4
ng/106 PMNL with 2 and 3 mri EDTA, respectively.
The results of the studies with verapamil are shown in Figure
4. The lower concentration of verapamil (l05M) had no effect
on both the spontaneous and the 1-84 PTH-induced release of
elastase from PMNL; the higher concentrations produced sig-
nificant and comparable decrements in the plasma levels of
elastase after incubation with both vehicle or 1-84 PTH. Vera-
pamil, however, did not abolish the stimulatory effect of 1-84
PTH on elastase release.
Since PMA was dissolved on DMSO, we first examined the
effect of DMSO alone on elastase release. DMSO by itself did
not have a significant stimulatory effect on elastase release after
Discussion
Although elastase may be released from other cell compo-
nents of blood, it is considered a marker of PMNL [29].
Elastase activity is detected in platelets [30] but platelet elastase
is present in very small concentration and is different from that
of PMNL [31]. Also, monocytes have elastase but its concen-
tration is less than 3% of that of PMNL [32]. It is, therefore,
reasonable to assume that the bulk of elastase measured in our
studies was released by PMNL.
The results of the present study demonstrate that intact 1-84
PTH produced a marked and significant increase in release of
elastase from human PMNL in a dose dependent manner.
Several observations in our study indicate that this effect is
specific to the hormone, is related to its biological activity and
is not due to impurities in the Sigma preparation of the
hormone. First, other peptide hormones such as insulin, calci-
tonin and ACTH did not augment elastase release by PMN;
second, inactivation of 1-84 PTH abolished its effect; and third,
pure 1-84 PTH had an effect on elastase release from PMNL
similar to that produced by Sigma 1-84 PTH.
It is generally accepted that the biological activity of PTH
resides on its aminoterminal fragment, and this notion is based
on the ability of this fragment to increase cAMP production by
the kidney [33] and to mobilize calcium from bone [34]. Thus
the finding that 1-34 PTH did not have an effect on elastase
release from PMNL, and therefore, is inert in this system,
appears surprising. However, other studies have shown that the
intact hormone and not its aminoterminal fragment affects
random motility of PMNL [24], platelet aggregation [35] and
hepatic glucose release [36]. All these observations suggest that
either the intact hormone is needed to exert these effects, or
these actions are due to biological activity that resides in the
Fig. 4. The effects of various concentrations
of verapamil on the spontaneous and 1-84
PTH-induced elastase release from PMN
leucocytes. Each column represents the mean
value observed in 7 normal subjects and the
bracket denotes 1 5E. All the values with 1-84
PTH are significantly higher than those with
vehicle (P < 0.01). Symbols are: () vehicle,10 M () 1-84 PTH 4 jig/mI; (•) verapamil; ()
Verampamil 1-84 PTH 4 jig/mI + verapamil.
Table 2. Effect of 0.25 x iO PMA, of PMA and various Table 3. Effect of 1-84 PTH, PTH and W-7, PTH and Staurosporin
concentration of staurosporin and of PMA and EDTA on elastase on elastase release from PMNL (N = 6)
release from PMNL (N = 6) Plasma Eal-PI
ng/106 PMNLPlasma Eal-PI
ng/106 PMNL
Basal 33.8 9.1
Vehicle
PMA 0.25 x 10-6
PMA + Staurosporin 1O
222.6 34.1
400.0 8486
317.0 64.8"
PMA + Staurosporin 0.5 x l0- 287.0 54,0b
PMA + Staurosporin 10—8 402.3 83.8
PMA + Staurosporin l0 409.7 85.2
PMA + EDTA 4 mM 42.9 4.lc
a P < 0.01 versus vehicle
b P < 0.01 versus PMA alone
P < 0.01 versus vehicle, PMA alone and PMA and Staurosporin
carboxyterminal fragment of the hormone. Indeed, our data
support the latter notion in that the carboxyterminal fragment,
19-84 PTH, produced similar and comparable effect to that of
1-84 PTH on elastase release from PMNL. Although this new
observation appears provocative, it is in agreement with other
recent data demonstrating the presence of binding sites with
specificity for middle region or carboxyterminal fragment of
PTH in canine and chicken renal membranes and in cloned rat
osteosarcoma cells [37—391.
Kokot et al [14] have shown that the calcium ionophore
A23 187 induced release of elastase from PMNL in a dose
dependent manner and this effect was abolished by EDTA.
They concluded that the effect of the calcium ionophore was
due to translocation of calcium form extracellular space to the
cytosol of the PMNL. It appears from our study that the action
of PTH on elastase release form PMNL is also mediated by
Basal 34.5 5.2
Vehicle 159.7 47.7
1-84 PTH 4 jig/mI 257.8 62.6a
1-84 PTH and Staurosporin 107M 217.0 55.1"
1-84 PTH and W-7 25 jiM 214.3 56.7"
a P < 0.02 versus vehicle
"P < 0.02 versus 1-84 PTH alone
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influx of calcium into the PMNL. PTH is known to augment
calcium entry into many cells [18—231 and the lack of an effect of
PTH in the presence of 2,3, or4 mi EDTA supports the notion
that its action on elastase release is due to its ability to enhance
entry of calcium into the PMNL.
Verapamil blocks voltage-sensitive calcium channels [40]
which may not be present in neutrophils [41]. Thus, it is not
surprising that verapamil did not abolish the effect of PTH on
elastase release from PMNL. The finding, however, that vera-
pamil in concentrations of l0 to 0.5 X 104M significantly
reduced the effects of PTH on elastase release suggests that
verapamil may exert this effect via other pathways. At least two
lines of evidence support this notion. First, Kokot et al [14]
found that verapamil inhibited PMNL-induced release of
elastase in a calcium free media. Second, Greenberg et al [42]
reported that verapamil exerted an inhibitory effect on NaF
stimulated neutrophil without reducing NaF induced rise in
cytosolic calcium. Verapamil is a lipophilic compound and can
readily penetrate the cell membrane [43]. One may speculate
that verapamil may internalize into the PMNL, affect the
50—.0' (1
Fig. 5. The effects of4 ig/ml of 1-84 PTH (a), PMA (U) 0.05 x 106
M, and 1-84 PTH (4 g/ml) and PMA () 0.05 x 106 M on elastase
release from PMNL. Symbol (U) is vehicle. Each column represents
mean values observed in 5 normal subjects and bracket denotes 1 SE.
The values with 1-84 PTH or PMA are significantly higher than that of
vehicle (P < 0.01) and the value with 1-84 PT1-1 and PMA are
significantly higher than those with 1-84 PTH or PMA alone (P < 0.05).
function of subcellular structures and hence exert an effect on
elastase release. Our study was not designed to examine the
effects of verapamil on elastase release from PMNL and,
therefore, can not provide insight on the mechanisms through
which verapamil inhibits or interferes with PTH-induced
elastase release.
PMA, an agent that activates protein kinase C [44], also
produced significant release of elastase from PMNL, suggesting
that protein kinase C plays an important role in this process.
This observation is in agreement with that of Kokot et al [14]
who also found that PMA stimulates elastase release from
PMNL. Protein kinase C may have a calcium-sensitizing effect
on cellular processes responsible for elastase release. It is
interesting that PMA does not promote an apparent rise in
PMNL cytosolic calcium but it enhances the affinity of protein
kinase C to calcium resulting in activation of the enzyme at
normal intracellular calcium levels [451. Theoretically, any
agent that may raise intracellular calcium concentration, such
as PTH, in the presence of PMA may enhance the activation of
protein kinase C. This combination of events may provide an
explanation for the significantly higher elastase release from
0-—— ——
Fig. 6. The effect of trifluoperazine on spontaneous and 1-84 PTH-
induced release of elastase from PMNL. Each column represents mean
value observed in 5 normal subjects and the bracket denotes 1 SE. The
value with 1-84 PTH and trifluoperazine is significantly lower than that
with 1-84 PTH alone (P < 0.01). Symbols are: (LI) vehicle; (U)
trifiuroperazine l0— M; () 1-84 PTH 4 g/ml; (0) trifluoperazine l0—
M + 1-84 PTH 4 tg/ml.
PMNL when both PMA and PTH were applied together.
Support for such a notion is found in our finding and in the
observation of Kokot et a! [14] that the stimulation of elastase
release from PMNL by PMA was significantly lower in the
presence of EDTA. The latter inhibits calcium influx into
PMNL and hence modulates the effect of PMA. The demon-
stration by our study that staurosporin, an inhibitor of protein
kinase C, produced a significant inhibition of both PTH or
PMA-induced elastase release from PMNL supports a role for
activation of protein kinase C in this process.
Our finding that PTH in the presence of EDTA did not
stimulate elastase release from PMNL suggests that the hor-
mone does not directly stimulate protein kinase C of PMNL or
trigger cellular events, such as phospholipid turnover, that
would generate diacyiglycerol which would stimulate protein
kinase C. However, the effects of PTH on phospholipid turn-
over has not been evaluated in our study and hence our data do
not support or rule out such a possibility.
The demonstration that trifluoperazine and W-7 (inhibitors of
calmodulin) caused a significant reduction in PTH-induced
elastase release from PMNL suggests that calmodulin is in-
volved in the cellular sequence of events that lead to the release
of elastase from PMNL by PTH. It should be mentioned,
however, that inhibitors of calmodulin could act as calcium
channel blockers. Ehrlich et al [46] have demonstrated that
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calcium channels in Paramecium are blocked by a family of
calmodulin antagonists. Therefore, the inhibitory effect of tn-
fluoperazine and W-7 on elastase release could also be medi-
ated, at least in part, by the potential possibility that these
compounds can block calcium entery into PMNL.
Taken together, our results indicate that the action of PTH on
elastase release from PMNL is mediated by the ability of the
hormone to enhance entry of calcium into cells. The rise in
intracellular calcium would activate calmodulin which then
mediate other cellular events that would cause elastase release.
Further, our data suggest that the PTH-induced release of
elastaese from PMNL would be enhanced in the presence of
other agonists that directly or indirectly stimulate protein
kinase C activity.
Finally, we would like to emphasize that our data was
obtained during acute exposure of PMNL to PTH. Such an
acute effect of the hormone may participate in the genesis of the
increased release of elastase from PMNL in patients with acute
renal failure who develop acute elevation of blood levels of
PTH [15]. The effects of chronic exposure of PMNL to high
concentrations of PTH, as in patients with chronic renal failure,
on elastase release could not be defined from our data. Addi-
tional studies are needed to elucidate this issue.
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